Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
National Institute of Allergy and Infectious Diseases (NIAID) |
---|---|
Information provided by: | National Institutes of Health Clinical Center (CC) |
ClinicalTrials.gov Identifier: | NCT00001409 |
Certain patients enrolled in NIH protocol 94-I-0206 at the Clinical Center may be eligible to participate in one or more of the following new options:
Condition | Intervention | Phase |
---|---|---|
Acquired Immunodeficiency Syndrome HIV Infection |
Drug: Interleukin-2 |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Safety Study |
Official Title: | A Phase I/II Pilot Study of the Safety of the Adoptive Transfer of Syngeneic Gene-Modified Cytotoxic T Lymphocytes in HIV Infected Identical Twins |
Estimated Enrollment: | 100 |
Study Start Date: | September 1994 |
Estimated Study Completion Date: | June 2002 |
Open-label, comparative, sequentially randomized treatment with genetically unmodified or modified ex vivo-expanded T-lymphocytes in patients with HIV infection who possess a seronegative syngeneic twin. Genetic modification consists of introduction of a gene for HLA-unrestricted "universal" receptors specific for the gp120 HIV envelope protein. Treatment is divided into Periods I and II.
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
INCLUSION CRITERIA:
An identical twin pair, one of whom is seropositive for HIV, the other twin seronegative, by standard ELISA, PCR, and Western blot testing.
Patients whose CD4+ count is less than 500/mm(3) at entry must have been on FDA-approved or expanded-access antiretroviral agent(s) for at least 2 months.
Patients with Kaposi's sarcoma are eligible for this study, but must not have received any systemic therapy for KS within 4 weeks prior to entry. The diagnosis of KS must have been confirmed by biopsy.
Anticipated survival greater than 6 months and Karnofsky Performance Status greater than or equal to 60%.
Males or females 18 years of age or older. Every effort will be made to include both genders.
Free from serious psychological or emotional illness and able to provide written informed consent.
EXCLUSION CRITERIA - RECIPIENT:
Lymphoma.
Unwillingness to comply with current NIH Clinical Center guidelines concerning appropriate notification of all current sexual partners of an individual regarding his or her HIV positive sero-status and the risk of transmission of HIV infection.
Recent history of substance abuse unless evidence is provided of an ongoing therapeutic intervention (i.e. medical therapy or counseling) to control such abuse.
Pregnancy at entry or unwillingness to practice barrier birth control or abstinence during the study.
EXCLUSION CRITERIA - DONOR:
Untreated or inadequately treated medical condition (e.g., cardiopulmonary disease, acute infection) which, in the judgement of the Principal Investigator, precludes apheresis.
Serologic positivity for Epstein Barr virus, Cytomegalovirus, Hepatitis B or Hepatitis C if and only if the recipient twin tests seronegative for the corresponding virus.
Study ID Numbers: | 940206, 94-I-0206 |
Study First Received: | November 3, 1999 |
Last Updated: | March 3, 2008 |
ClinicalTrials.gov Identifier: | NCT00001409 |
Health Authority: | United States: Federal Government |
AIDS Gene Therapy T Cell Universal Receptor Ex Vivo Activation |
Virus Diseases Sexually Transmitted Diseases, Viral Interleukin-2 HIV Infections |
Sexually Transmitted Diseases Acquired Immunodeficiency Syndrome Retroviridae Infections Immunologic Deficiency Syndromes |
RNA Virus Infections Slow Virus Diseases Disease Immune System Diseases Antineoplastic Agents Physiological Effects of Drugs Infection Pharmacologic Actions Pathologic Processes |
Sensory System Agents Analgesics, Non-Narcotic Syndrome Therapeutic Uses Lentivirus Infections Peripheral Nervous System Agents Analgesics Central Nervous System Agents |